The P4 region of a series of oxamyl dipeptide caspase inhibitors was optimized by the combination of anti-apoptotic activity in the Jurkat/Fas (JFas) cellular assay and membrane permeability in the PAMPA assay. Two highly potent anti-apoptotic agents with moderate membrane permeability, 29 and 36, showed strong in vivo efficacy in a murine model of alpha-Fas-induced liver injury.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2008.10.117 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis and structure-activity relationships of oxamyl dipeptide caspase inhibitors developed for the treatment of liver disease.
Bioorg Med Chem Lett
January 2009
Discovery Chemistry Research, Pfizer Global Research and Development, Nagoya Laboratories, Pfizer Japan Inc, Aichi, Japan.
The P4 region of a series of oxamyl dipeptide caspase inhibitors was optimized by the combination of anti-apoptotic activity in the Jurkat/Fas (JFas) cellular assay and membrane permeability in the PAMPA assay. Two highly potent anti-apoptotic agents with moderate membrane permeability, 29 and 36, showed strong in vivo efficacy in a murine model of alpha-Fas-induced liver injury.
View Article and Find Full Text PDFFirst-in-class pan caspase inhibitor developed for the treatment of liver disease.
J Med Chem
November 2005
Idun Pharmaceuticals, 9380 Judicial Drive, San Diego, CA 92121, USA.
A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of alpha-Fas-induced liver injury.
View Article and Find Full Text PDFOxamyl dipeptide caspase inhibitors developed for the treatment of stroke.
Bioorg Med Chem Lett
May 2004
Idun Pharmaceuticals, Inc., 9380 Judicial Drive, San Diego, CA 92121, USA.
Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!